2-(三氟甲基磺酰氧基)戊酸乙酯 | 109684-05-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: 2-(三氟甲基磺酰氧基)戊酸乙酯
• 英文名称: ethyl 2-([(trifluoromethyl)sulphonyl]oxy)pentanoate
• 英文别名: rac-ethyl 2-{[(trifluoromethyl)sulfonyl]oxy}pentanoate；ethyl DL-2-trifluoromethylsulfonyloxypentanoate；ethyl 2-(trifluoromethylsulfonyloxy)pentanoate
• CAS: 109684-05-1
• 化学式: C₈H₁₃F₃O₅S
• 分子量: 278.249
• InChiKey: QQGABBCSGGJCFO-UHFFFAOYSA-N

物化性质

• 沸点：
  263.1±40.0 °C(Predicted)
• 密度：
  1.336±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-(三氟甲基磺酰氧基)戊酸乙酯 在 aluminum oxide 、 potassium fluoride 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 96.0h， 生成 (E)-ethyl 2-benzylidenepentanoate
  参考文献：
  名称：

  1-Alkoxycarbonylalkylidenetriphenylarsoranes: Preparation and reactions

  摘要：

  The higher homologues of the well-studied alkoxycarbonylmethylenetriphenylarsonium(1) ylide (3, R=H) can be easily obtained through the sequence: a). preparation of alkyl 2-trifloxyalkanoates (1); b), reaction between these trifloxyderivatives and triphenylphosphine to give 1-alkoxycarbonylalkyltriphenylarsonium triflates (2); and c), basic treatment of the triphenylarsonium triflates (2) with alumina-supported potassium fluoride to give 1-alkoxycarbonylalkyledenetriphenylarsonium ylides (3). These higher homologues of(3, R=H) react with aromatic aldehydes in good to excellent yields. and give rise to synthetically interesting ''coupling'' and cyclopropanation reactions.

  DOI：

  10.1016/s0040-4020(01)85688-x
• 作为产物：
  描述：

  2-羟基戊酸乙酯 在 吡啶 、 trifluoromethanesulfonic acid anhydride 作用下， 以 二氯甲烷 为溶剂， 生成 2-(三氟甲基磺酰氧基)戊酸乙酯
  参考文献：
  名称：

  Compounds having a cognition adjuvant action, agents containing them,

  摘要：

  本发明涉及一种具有认知辅助作用的新化合物，以及将ACE抑制剂用作具有认知辅助作用的药物，包含它们的制剂，以及将其用于治疗和预防认知功能障碍的用途。

  公开号：

  US05231084A1

文献信息

• Copper-Catalyzed Substitution of α-Triflyloxy Nitriles and Esters with Silicon Nucleophiles under Inversion of the Configuration
  作者：Jonas Scharfbier、Hamideh Hazrati、Elisabeth Irran、Martin Oestreich

  DOI：10.1021/acs.orglett.7b03279

  日期：2017.12.15

  A copper-catalyzed nucleophilic displacement of α-triflyloxy nitriles and esters with silicon nucleophiles allows for the stereospecific generation of highly enantioenriched α-silylated carboxyl compounds. The enantioselective synthesis of α-silylated nitriles is unprecedented. The catalytic system exhibits good functional group tolerance. The stereochemical course of the substitution is shown to proceed

  铜催化的α-三氟乙腈和酯与硅亲核试剂的亲核取代反应可以立体定向生成高度对映体富集的α-甲硅烷基化的羧基化合物。α-甲硅烷基化腈的对映选择性合成是前所未有的。催化体系表现出良好的官能团耐受性。取代的立体化学过程显示为反转构型。新的反应是对催化C（sp 3）-Si交叉偶联方法数量仍然有限的补充。
• Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats
  作者：Colin Bennion、Roger C. Brown、Anthony R. Cook、Carol N. Manners、David W. Payling、David H. Robinson

  DOI：10.1021/jm00105a066

  日期：1991.1

  containing inhibitors of angiotensin converting enzyme have been designed and synthesized. The compounds are highly potent enzyme inhibitors and, as a consequence of conformational restriction, chemically stable with respect to undesirable cyclization reactions. The most interesting compound from this series, 5a (FPL 63547), is the monoethyl ester prodrug of the highly potent "aminocarboxy" inhibitor 5b (FPL

  设计并合成了两个新系列的含二氢噻二唑环的血管紧张素转化酶抑制剂。该化合物是高效的酶抑制剂，并且由于构象限制，对于不希望的环化反应而言是化学稳定的。该系列中最有趣的化合物5a（FPL 63547）是高效的“氨基羧基”抑制剂5b（FPL 63674）的单乙酯前药。口服给药后，可在动物模型中长期产生降压作用。与其他ACE抑制剂不同，大鼠体内的胆汁清除几乎消除了5b。根据5a和5b的独特理化特性，合理化了其药理特性。用5b观察到的对胆道清除的明显偏爱与其亲脂性和在生理pH下的高净离子化程度相一致，这是由于C端羧酸功能的pKa值非常低所致。FPL 63547目前正在人体中进行临床研究。
• 1,3,4-thiadiazoles
  申请人：Fisons plc

  公开号：US04927822A1

  公开（公告）日：1990-05-22

  There are described compounds of formula I, ##STR1## in which Y is S, O or NR.sub.9, n is 0 or 1, R.sub.9 is hydrogen or alkyl C 1 to 10, R.sub.3 is hydrogen, alkyl C 1 to 10, cycloalkyl C3 to 10, CF.sub.3, SR.sub.10, a 5 or 6 membered heterocyclic group containing one or more S, O or N atoms, NR.sub.4 R.sub.5, phenyl or phenylalkyl C7 to 12, the phenyl, phenylalkyl and heterocyclic groups optionally being fused to a further phenyl group, the heterocyclic group and any phenyl group optionally being substituted by alkyl C 1 to 6, halogen, alkoxy C 1 to 6, nitro, nitrile, CF.sub.3, SR.sub.6, NR.sub.7 R.sub.11 or hydroxy, R.sub.6, R.sub.7 and R.sub.11, which may be the same or different, are each hydrogen or alkyl C 1 to 10, R.sub.4 and R.sub.5, which may be the same or different, are each hydrogen, alkyl C 1 to 10 or phenyl, R.sub.10 is alkyl C 1 to 10, X.sub.1 is S or O, and A is a chain comprising from 2-16 atoms, which chain carries an O or S containing substitutent at a position 2-6 atoms away from the group C=X.sub.1, and pharmaceutically acceptable salts, esters and amides thereof, p1 there are also described method of making the compounds and pharmaceutical formulations, e.g. for the treatment of hypertension, containing them.

  描述了一种式子为I的化合物，其中Y为S、O或NR.sub.9，n为0或1，R.sub.9为氢或烷基C1到C10，R.sub.3为氢、烷基C1到C10、环烷基C3到C10、CF.sub.3、SR.sub.10、含有一个或多个S、O或N原子的5或6元杂环基、NR.sub.4R.sub.5、苯基或苯基烷基C7到C12，其中苯基、苯基烷基和杂环基可以选择与另一个苯基基团融合，杂环基和任何苯基基团可以选择被烷基C1到C6、卤素、烷氧基C1到C6、硝基、腈基、CF.sub.3、SR.sub.6、NR.sub.7R.sub.11或羟基取代，R.sub.6、R.sub.7和R.sub.11可以相同也可以不同，分别为氢或烷基C1到C10，R.sub.4和R.sub.5可以相同也可以不同，分别为氢、烷基C1到C10或苯基，R.sub.10为烷基C1到C10，X.sub.1为S或O，A为由2-16个原子组成的链，在距离C=X.sub.1基团2-6个原子处携带一个含O或S的取代基，以及其药学上可接受的盐、酯和酰胺。此外还描述了制备这些化合物和制备它们的药物配方的方法，例如用于治疗高血压。
• [EN] NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING<br/>[FR] NOUVEL AGENT DE CONTRASTE DESTINÉ À ÊTRE UTILISÉ DANS L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE
  申请人：BAYER AG

  公开号：WO2022194777A1

  公开（公告）日：2022-09-22

  The present invention relates to a new class of compounds of general formula (I), the Gd3+chelate complexes thereof, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents. Formula (I)

  本发明涉及一类新的通式（I）化合物、其钆3+螯合物、制备上述化合物的方法以及上述化合物作为 MRI 造影剂的用途。通式 (I)
• 5-membered heterocyclic ring angiotensin converting enzyme inhibitors
  申请人：FISONS plc

  公开号：EP0217519A1

  公开（公告）日：1987-04-08

  There are described compounds of formula I, in which Y is S, 0 or NR9, n is 0 or 1, R9 is hydrogen or alkyl C 1 to 10, R3 is hydrogen, alkyl C 1 to 10, cycloalkyl C3 to 10, CF3, SR10, a 5 or 6 membered heterocyclic group containing one or more S, O or N atoms, NR4R5, phenyl or phenylalkyl C7 to 12, the phenyl, phenylalkyl and heterocyclic groups optionally being fused to a further phenyl group, the heterocyclic group and any phenyl group optionally being substituted by alkyl C 1 to 6, halogen, alkoxy C 1 to 6, nitro, nitrile, CF3, SR6, NR7R11 or hydroxy, R6, R7 and R,,, which may be the same or different, are each hydrogen or alkyl C 1 to 10, R, and Rs, which may be the same or different, are each hydrogen, alkyl C 1 to 10 or phenyl, R,10 is alkyl C 1 to 10, X, is S or 0, and D is a chain comprising from 2 -16 atoms, which chain carries an O or S containing substituent at a position 2 -6 atoms away from the group C=X,, and pharmaceutically acceptable salts, esters and amides thereof, there are also described methods for making the compounds and pharmaceutical formulations, eg for the treatment of hypertension, containing them.

  所述化合物为式 I、 其中 Y 是 S、0 或 NR9、 n 是 0 或 1、 R9 是氢或 C 1-10 烷基、 R3 是氢、C 1 至 10 烷基、C3 至 10 环烷基、CF3、SR10、含有一个或多个 S、O 或 N 原子的 5 或 6 位杂环基团、NR4R5、苯基或 C7 至 12 苯烷基，其中苯基、苯烷基和杂环基团可选、苯基、苯基烷基和杂环基可选择与另一个苯基融合，杂环基和任何苯基可选择被 C1-6 烷基、卤素、C1-6 烷氧基、硝基、腈基、CF3、SR6、NR7R11 或羟基取代、 R6、R7 和 R，可以相同或不同，各自为氢或 C 1 至 10 烷基、 R,和 Rs，可以相同或不同，各自为氢、C 1-10 烷基或苯基、 R，10 为 C 1-10 烷基、 X 是 S 或 0，以及 D 是由 2 -16 个原子组成的链，该链在距离基团 C=X, 2 -6 个原子的位置上带有一个含 O 或 S 的取代基、 及其药学上可接受的盐、酯和酰胺、 还描述了制造这些化合物和药物制剂（例如用于治疗高血压）的方法。